Established multi-location opioid treatment and outpatient substance use disorder platform serving Western Pennsylvania. The business operates three licensed treatment locations with an established patient base, experienced clinical infrastructure, payer relationships and a recurring treatment model.

The platform includes an operating Opioid Treatment Program providing methadone maintenance, along with buprenorphine-based medications for opioid use disorder, outpatient substance use disorder treatment, counseling and medication management services.

The three licensed treatment locations currently serve approximately 471 patients against combined licensed capacity of approximately 1,085 patients, providing meaningful opportunity for additional growth within the existing footprint.

The opportunity may be particularly attractive to an existing behavioral health operator, addiction treatment provider, OTP operator or strategic healthcare acquirer seeking an established Western Pennsylvania presence without developing a comparable platform from the ground up.

Growth opportunities include increasing patient census, expanding referral relationships, improving utilization of existing licensed capacity, growing complementary outpatient services and leveraging existing clinical, billing and administrative infrastructure across a larger platform.

2026 expected platform revenue is approximately $1.96 million.

Ownership is pursuing a sale of the operating businesses. Related real estate at one location may also be available separately. Detailed financial information, census data, payer information, licensing materials and additional operating information will be provided to qualified buyers following execution of a confidentiality agreement.